Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

BACKGROUND: A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1. OBJECTIVE: The objective of this study...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drugs R D
Asıl Yazarlar: Garimella, Tushar, Tao, Xiaolu, Sims, Karen, Chang, Yi-Ting, Rana, Jignasa, Myers, Elsa, Wind-Rotolo, Megan, Bhatnagar, Rahul, Eley, Timothy, LaCreta, Frank, AbuTarif, Malaz
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2017
Konular:
Original Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833906/
https://ncbi.nlm.nih.gov/pubmed/29255971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-017-0222-8
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller